Pedro Ferrari Sales da Cunha

Pedro Ferrari Sales da Cunha

Auto-generated profile, based on publicly available information

Pedro Ferrari Sales da Cunha

Hospital Metropolitano Odilon Behrens, Belo Horizonte, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2020 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
FPFrancisco Guilherme Cancela e Penna
Francisco Guilherme Cancela e Penna
RRRodrigo Macedo Rosa
Rodrigo Macedo Rosa
PCPedro Ferrari Sales da Cunha
Pedro Ferrari Sales da Cunha
SSStella Cristina Silva de Souza
Stella Cristina Silva de Souza
MFMaria de Lourdes de Abreu Ferrari
Maria de Lourdes de Abreu Ferrari
Background: Effective control of the inflammatory process in Crohn’s disease (CD) is reflected in intestinal mucosal healing. The performances of faecal calprotectin (fcal), clinical and serologic parameters in the inflammatory activity evaluation and their correlation to the simple endoscopic score (SES-CD) are the goals of this study. Methods: Patients with CD referred for ileocolonoscopy were prospectively included and distributed according to the degree of endoscopic inflammatory activity into remission, mild activity, and moderate to severe activity groups. The different degrees of endoscopic activity were correlated with the following indexes: Crohn’s disease activity index (CDAI), fCal, serum C-reactive protein (CRP), and haemogram. The control group comprised individuals without known intestinal disease who were referred for colorectal cancer screening. Results: Eighty colonoscopies were performed in patients with CD and 21 in the control group. The control group had a lower median fCal (59.7 mcg/g) than patients with CD (683 mcg/g, p < 0.001). A moderate Spearman correlation occurred between SES-CD and CRP (r = 0.525), fCal (r = 0.450), and CDAI (r = 0.407), while a weak correlation was found with the platelet count (r = 0.257). Only fCal distinguished patients in remission from those with mild activity (236.6 mcg/g × 654.9 mcg/g, p = 0.014) or moderate to severe activity (236.6 mcg/g × 1128 mcg/g, p < 0.001). An fCal cut-off of 155 mcg/g was sensitive (96%) and accurate (78%) for the diagnosis of endoscopic activity. Conclusions: fCal provides greater diagnostic accuracy than the other activity markers for endoscopic activity of patients with CD, moderate correlation to SES-CD, and a capacity to discriminate patients in remission from those with mild or moderate to severe activity.

1 February 2021 in Gastroenterología y Hepatología
Verified
Journal Article
Closed access
FPFrancisco Guilherme Cancela e Penna
Francisco Guilherme Cancela e Penna
RRRodrigo Macedo Rosa
Rodrigo Macedo Rosa
FPFernando H. Pereira
Fernando H. Pereira
PCPedro Ferrari Sales Cunha
Pedro Ferrari Sales Cunha
SSStella Cristina S. Sousa
Stella Cristina S. Sousa
MFMaria de Lourdes A. Ferrari
Maria de Lourdes A. Ferrari

15 January 2025 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
LMLuanna Silva Monteiro Menezes
Luanna Silva Monteiro Menezes
PCPedro Ferrari Sales da Cunha
Pedro Ferrari Sales da Cunha
MPMagda Carvalho Pires
Magda Carvalho Pires
LVLucas Rocha Valle
Lucas Rocha Valle
FCFlávia Carvalho Cardoso Costa
Flávia Carvalho Cardoso Costa
MMMilena Soriano Marcolino
Milena Soriano Marcolino
Cirrhosis has been pointed out as a clinical entity that leads to worse clinical prognosis in COVID-19 patients. However, this concept is controversial in the literature. We aimed to evaluate clinical outcomes by comparing patients with cirrhosis to those without cirrhosis in a Brazilian cohort. Data from 20,164 COVID-19 inpatients were collected from 41 hospitals in Brazil between March to September 2020 and March 2021 to August 2022. We compared 117 patients with cirrhosis to 632 matched controls. A propensity score model was used to adjust for potential confounding variables, incorporating some predictors: age, sex at birth, number of comorbidities, hospital of admission, whether it was an in-hospital clinical manifestation of COVID-19, and admission year. Closeness was defined as being within 0.16 standard deviations of the logit of the propensity score. The median age was 61 (IQR 50–70) years old, and 63.4% were men. There were no significant differences in the self-reported symptoms. Patients with cirrhosis had lower median hemoglobin levels (10.8 vs. 13.1 g/dl), lower platelets (127,000 vs. 200,000 cells/mm3), and leukocyte counts, as well as lower median C-reactive protein (63.0 vs. 76.0 p = 0.044) when compared to controls. They also had higher mortality compared to matched controls (51.3% vs. 21.7%, p < 0.001). They also had higher frequencies of admission in an intensive care unit (51.3% vs. 38.0%, p = 0.007), invasive mechanical ventilation (43.9% vs. 26.6%, p < 0.001), dialysis (17.9% vs. 11.1%, p = 0.038), septic shock (23.9% vs. 14.9%; p = 0.015) and institution of palliative care (19.7% vs. 7.4%; p < 0.001). This study has shown that COVID-19 inpatients with cirrhosis had significantly higher incidence of severe outcomes, as well as higher frequency of institution of palliative care when compared to matched controls. Our findings underscore the need for these patients to receive particular attention from healthcare teams and allocated resources.

18 February 2022 in Transactions of the Royal Society of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
TFTeresa Cristina Abreu Ferrari
Teresa Cristina Abreu Ferrari
AOAna Elisa M Oliveira
Ana Elisa M Oliveira
MLMaria Júlia S Logato
Maria Júlia S Logato
CGCarolina G Ganzella
Carolina G Ganzella
RMRodolfo Ferreira Q Melo
Rodolfo Ferreira Q Melo
ACAloísio S Cunha
Aloísio S Cunha
Background: Deposition of Schistosoma mansoni eggs in the brain of patients with hepatosplenic schistosomiasis (HS-SM) is frequent and usually asymptomatic. However, it is questioned whether it could cause seizures. Thus, we investigated the occurrence of seizures in these patients and also searched for parameters associated with this disorder. Methods: In a cross-sectional survey, we compared 128 patients with HS-SM with 102 patients with portal hypertension due to compensated chronic hepatic disease of other etiologies. A standardized questionnaire, emphasizing epilepsy-related parameters, was applied to all participants. Results: Eight (6.3%) patients with HS-SM had a history of seizures, whereas this condition was reported by three (2.9%) individuals from the comparison group (p=0.354). None of the variables were associated with the occurrence of seizures, either in univariate or in multivariate analysis. Conclusions: The frequency of seizures was similar in both study groups. However, it was higher than that described in population-based studies. Thus, we hypothesize that HS-SM individuals may have a higher frequency of seizure. The lack of difference between the two study groups may be explained by the inclusion of cases of HS-MS overlapping other chronic liver diseases in the comparison group, because this finding is relatively common in schistosome-endemic areas.